Wednesday, May 8, 2024

Vogon Today

Selected News from the Galaxy

StartMag

WHO pro Speranza, EU vaccine report card, Colao does not beat Huawei, Elkann’s requests to Draghi

3 years ago babelfish

WHO pro Speranza, EU vaccine report card, Colao does not beat Huawei, Elkann's requests to Draghi

Hope, WHO, Draghi, Johnson & Johnson, Stellantis, Colao, Huawei, Elkann and more. Facts, names, numbers, curiosities and controversies. The tweets of Michele Arnese, director of Start

THE EU REPORT ON VACCINES

THE MINISTER OF HEALTH RESIGNED. IN AUSTRIA

THE MINISTER OF HEALTH DOES NOT RESIGN. IN ITALY

BECAUSE HOPE REMAINS MINISTER

JUDICIAL CLOUDS ON THE MINISTRY OF HEALTH

WAR OF WHO SEEN BY ZAMBON FORMER WHO

VACCINES & PATENTS

VIRAL DATA

WHAT HAPPENED IN THE USA TO THE JOHNSON & JOHNSON VACCINE

WHAT IS SAYING IN THE USA ABOUT JOHNSON & JOHNSON

BIDEN'S VACCINE PLAN

AMERICAN MONEY FOR J&J VACCINE

THE NEW PLAN IN THE CONSTRUCTION SITE OF DRAGONS ON VACCINES

THE FUTURE OF VACCINES

VACCINES ACCORDING TO RASI EX EMA

THE BROADBAND IS WIDING

COLAO'S THOUGHTS ON THE NET ACCORDING TO THE SUN

COLAO DOES NOT BEAT ON HUAWEI

THE REQUESTS OF STELLANTIS TO DRAGHI

THE DIETROLOGIES OF BETTINI ON COUNT AND DRAGONS

QUISQUILIE & PINZILLACCHERE

+++

EXCERPT FROM AN ARTICLE FROM CORRIERE DELLA SERA ABOUT JOHNSON & JOHNSON:

The American federal authorities "recommend a pause" in the spread of the Johnson & Johnson vaccine, as a "measure of extreme caution." Reason? "Some cases of severe reaction" to serum. Within two weeks of the injection, six women, between the ages of 18 and 48, contracted a rare form of the disease, with blood clots. One is dead, another is "in critical condition".

The Food and Drug Administration (Fda) and the Centers for Disease and Control Prevention (CDC) have released an unusual joint statement: "We recommend a break, even if at the moment these adverse events appear to be extremely rare." Six cases out of approximately 6.8 million Johnson & Johnson doses administered so far. "Less than one episode in a million," noted virologist Anthony Fauci who added: "The suspension will last a few days or a week, not a month." In a note, the company specified: "For now, a clear relationship has not been established between these rare events and our vaccine."

The CDC has called for today "an extraordinary meeting" of "independent experts". The data and medical records of the six patients will be examined. Then it will be up to the FDA to decide whether to place restrictions on the vaccine's readmission to the market, not recommending it, for example, to certain age groups. There are still no precise indications on this point.

The news, however, shook America. Scientists immediately brought up the problem that arose in Europe with AstraZeneca, while 30 out of 50 governors immediately excluded J&J from the vaccination campaign. For once, political or geographic differences have disappeared. They range from California to Florida, from Michigan to Ohio, from New York to Louisiana.

But the repercussions are worldwide. J&J has informed the Brussels Commission that it will delay the delivery of the planned vials, without clarifying, however, to what extent. The program called for the supply of 55 million doses by the end of June and another 120 million by the year. At the same time, the EMA, the European Agency for the Control of Drugs, announces that "since last week" it has been examining "reports of embolic events". Even the EMA is not unbalanced: "It is not clear whether there is a cause-effect relationship".

The use of J&J serum was approved by the FDA on February 27, after three weeks of data verification. The US government has staked a lot on it, financing the research, experimentation and production phases with almost two billion dollars. Even today it is considered a fundamental step to complete the vaccination campaign by the end of June. It is an easier product to use than Pfizer and Moderna, because it is single-dose and can be stored in normal refrigerators. Two features that facilitate widespread distribution even in the most peripheral areas.

The company committed to deliver approximately 100 million vials to the Federal Administration by May. But there have been several problems in the past few weeks. Some states, such as Georgia, Colorado, Iowa, had already blocked the administration after the first reports of thrombosis. And in the meantime, it turned out that 15 million doses had been ruined at an Emergent BioSolutions facility in Baltimore.

This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/mondo/oms-pro-speranza-nuovo-piano-draghi-sui-vaccini-colao-non-picchia-huawei-le-richieste-di-elkann-a-draghi/ on Wed, 14 Apr 2021 07:47:09 +0000.